PetIQ has acquired MYOS Corp and its portfolio of Fortetropin-based animal muscle health products, adding consumer supplements and veterinarian-exclusive formulations to its pet health and wellness platform.
The acquisition gives PetIQ ownership of the MYOS brand and patented Fortetropin ingredient technology. The products are designed to support muscle preservation, mobility and recovery in companion animals affected by aging, injury or surgery.
Fortetropin is a proprietary bioactive compound intended to influence myostatin, a naturally occurring regulator that limits muscle growth. MYOS says the ingredient has been studied in humans and animals, including dogs, cats and horses, and is supported by more than a dozen clinical studies and a portfolio of patents.
PetIQ plans to maintain the MYOS and Fortetropin names while incorporating the products into its broader health and wellness portfolio. The company can use its national retail, e-commerce, manufacturing and distribution capabilities to expand availability and introduce the products to more pet owners and veterinary customers.
The deal expands PetIQ beyond its established categories, which include over-the-counter flea and tick medications, dental treats, nutritional products and other wellness offerings. Its brands include PetArmor, Capstar, Nextstar, Minties, VetIQ and Rocco & Roxie.
PetIQ is owned by Bansk Group, a consumer-focused investment firm managing more than $5 billion. Lincoln International and Davis Polk advised PetIQ and Bansk, while Class VI Partners and Davis Graham advised MYOS.
KEY QUOTES:
“Pet parents are increasingly looking for solutions that support their pets’ mobility, recovery, and long-term vitality, not just treatment after a problem arises. MYOS has spent over a decade working alongside veterinarians to understand the science around muscle health, leading to the development of Fortetropin as a proprietary, differentiated, clinically supported ingredient.”
“Adding MYOS to our leading branded portfolio allows us to enter the fast-growing muscle health category and meet pet owners’ growing interest in preventive health, mobility preservation, and quality of life for their pets. We are looking forward to working with the MYOS team and scaling the brand with our insights-first approach, brand building capabilities, and our national retail and e-commerce footprint.”
Camillo Pane, Chief Executive Officer of PetIQ
“We’re very excited to partner with PetIQ. PetIQ’s distribution reach, brand-building expertise, and operating discipline are exactly what MYOS and Fortetropin need to realize their full potential and reach more pet owners globally.”
Joe Mannello, CEO of MYOS Corp
